Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10528461 | 0.79 | MAPT (0.35) | MAPTSMN1; SMN2 | |
| SCHEMBL1122006 | 0.72 | IDO1 (0.48) | SMN1; SMN2 | |
| SCHEMBL29953348 | 0.72 | IDO1 (0.48) | SMN1; SMN2 | |
| SCHEMBL1569775 | 0.71 | CA3 (0.46) | LMNAMAPT | |
| SCHEMBL9027842 | 0.71 | ALDH1A1 (0.41) | LMNA | |
| SCHEMBL13185294 | 0.69 | IDO1 (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL2562083 | 0.69 | P2RX7 (0.38) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2559866 | 0.69 | ALDH1A1 (0.44) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30515582 | 0.69 | ALDH1A1 (0.44) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30681287 | 0.69 | PKM (0.39) | LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | LMNA 753/4885MAPT 3666/4885SMN1; SMN2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.